Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Point-Of-Care International Normalized Ratio (INR) Testing Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The point-of-care inr testing market has experienced considerable growth in recent years. It is anticipated to expand from $1.58 billion in 2025 to $1.75 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.4%. Historically, this expansion has been propelled by factors such as an escalating prevalence of cardiovascular diseases, an increase in the use of anticoagulant therapy, a rising incidence of atrial fibrillation, the development of outpatient and homecare environments, and a heightened requirement for rapid coagulation testing.
The point-of-care inr testing market is anticipated to experience rapid expansion over the next few years. It is projected to grow to $2.56 billion in 2030, achieving a compound annual growth rate (CAGR) of 10.1%. This growth during the forecast period is propelled by factors such as the increasing demand for monitoring at home, a growing elderly demographic requiring long-term anticoagulation, a heightened focus on personalized anticoagulation management, the broadening of decentralized healthcare models, and increased adoption within primary care clinics. Key trends for the forecast period include technological advancements in portable coagulation analyzers, innovations in biosensor and microfluidic technologies, progress in wireless connectivity and data integration, ongoing research and development for high-accuracy test strips, and advancements in smartphone-enabled inr testing.
Get A Free Sample Report With In-Depth Market Insights:
Point-Of-Care International Normalized Ratio (INR) Testing Market Growth Momentum: What Factors Are Shaping Demand?
The increasing occurrence of cardiovascular conditions is projected to drive the expansion of the point-of-care International Normalized Ratio (INR) testing market in the future. These diseases encompass ailments impacting the heart and circulatory system, such as heart attacks, strokes, and high blood pressure. The rise in cardiovascular diseases is attributed to unhealthy lifestyle choices, including inadequate nutrition, insufficient physical activity, and tobacco use. Point-of-care International Normalized Ratio (INR) testing assists in the diagnosis of cardiovascular diseases by facilitating quick evaluation of blood clotting status either at a patient’s bedside or in a clinical setting. This method enhances clinical judgment through its support for prompt identification of coagulation irregularities and its guidance for anticoagulation treatment. For example, data from October 2024, provided by the US government agency, the Centers for Disease Control, indicates that in 2023, around 919,032 individuals succumbed to cardiovascular disease, representing one in every three fatalities. Consequently, the growing incidence of cardiovascular illnesses is fueling the expansion of the point-of-care International Normalized Ratio (INR) testing market.
Point-Of-Care International Normalized Ratio (INR) Testing Market Segment Outlook: Which Categories Are Growing Fastest?
The point-of-care international normalized ratio (inr) testing market covered in this report is segmented –
1) By Product Type: Devices, Consumables, Software
2) By Technology: Electrochemical, Optical, Others
3) By Distribution Channel: Direct Sales, Retail Pharmacies, Online Or E-Commerce, Others
4) By Application: Hospitals, Clinics, Home Care, Diagnostic Centers, Others
5) By End-User: Healthcare Professionals, Patients
Subsegments:
1) By Devices: Portable Testing Devices, Handheld Testing Devices, Desktop Testing Devices
2) By Consumables: Test Strips, Cartridges, Control Solutions
3) By Software: Data Management Software, Remote Monitoring Software, Analytical Software
Point-Of-Care International Normalized Ratio (INR) Testing Market Trends Redefining Industry Growth
Companies operating in the point-of-care International Normalized Ratio (INR) testing market are largely focusing on developing advanced products, such as patient self-monitoring coagulation analyzers, to broaden decentralized testing and shift recurring demand towards lower-cost consumables. Patient self-monitoring coagulation analyzers are portable instruments that allow individuals to perform PT/INR testing in their own homes using a minimal capillary blood sample, thereby supporting frequent monitoring and lessening dependence on clinical visits. As an illustration, in March 2024, Universal Biosensors, an Australia-based medical device company, unveiled the Xprecia Prime 4U Coagulation Analyzer for patient self-monitoring. This self-monitoring coagulation analyzer, which is designed to fit in the palm of a hand, yields rapid PT/INR results from a single drop of capillary blood and employs an electrochemical strip format that facilitates regulatory approvals, including 510(k) clearance and a CLIA waiver for the U.S. market. This introduction marks an important stride in INR testing by enabling wider availability of home monitoring, boosting test frequency, and improving cost efficiency through higher consumable utilization while maintaining clinical accuracy.
Point-Of-Care International Normalized Ratio (INR) Testing Market Industry Leaders And Competitive Landscape
Major companies operating in the point-of-care international normalized ratio (inr) testing market are Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton, Dickinson and Company, Hoffmann-La Roche Ltd., QuidelOrtho Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., Werfen S.A., HORIBA Ltd., Microvisk Ltd., Randox Laboratories Ltd., Nova Biomedical Corporation, Agappe Diagnostics Ltd., Visby Medical Inc., EKF Diagnostics Holdings plc, Trinity Biotech plc, HemoSonics LLC, Human Diagnostics Worldwide GmbH, CoaguSense Inc.
View The Full Point-Of-Care International Normalized Ratio (INR) Testing Market Report:
Point-Of-Care International Normalized Ratio (INR) Testing Market Regional Analysis And Leading Geography
North America was the largest region in the Point-of-Care INR Testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point-of-care international normalized ratio (inr) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model